What question did this study set out to answer?

To compare outcomes linked to dapagliflozin and empagliflozin in heart failure management.

December 8, 2025JAMA Network OpenOpen Access

Empagliflozin and Dapagliflozin Outcomes in Heart Failure

View Full Paper

Ask AI

Bookmark

Authors

Cohort study found similar clinical outcomes for dapagliflozin and empagliflozin in heart failure, suggesting their comparable effectiveness.

To compare outcomes linked to dapagliflozin and empagliflozin in heart failure management.
Cohort study of heart failure patients from 8 medical centers in Korea.
Patients received either dapagliflozin or empagliflozin and underwent transthoracic echocardiography.
One-to-one propensity score matching ensured comparable baseline characteristics.
No significant difference in primary outcome of cardiovascular death or hospitalization between dapagliflozin (9.8%) and empagliflozin (9.3%).
Results consistent across left ventricular ejection fraction subgroups (HF with reduced, mildly reduced, and preserved ejection fraction).
Secondary outcomes showed no significant differences between the treatments.

Bu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Cohort study found similar clinical outcomes for dapagliflozin and empagliflozin in heart failure, suggesting their comparable effectiveness.